ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
BCBSMN_PharmProgPolicyNotifctn_2021-0101v4.pdf
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 1731 - 1740 လၢ 3613 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
BC-COM_Med-Drug_Exclusion-LIST_Medcaid-2020-1112.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP64R2-20 Update: Medical Drug Update for Viltolarsen (Viltepso)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 11, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP107-20 Pharmacy Benefit Update – New and Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective January 1, 2021
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 11, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP108-20 Commercial Pharmacy Benefit Update – New Drug-Related Step Therapy (ST) with Quantity Limit (QL) Criteria: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Combinations
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 11, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP109-20 Commercial Pharmacy Benefit Update – New Drug-Related Step Therapy (ST) with Quantity Limit (QL) Criteria: Antiemetic Agents
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 11, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Upcoming_med_policies_effective_Jan_4_ 2021.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P50R2-20 Update: eviCore is Changing Prior Authorization Guidelines used to Review Durable Medical Equipment and Post-Acute Care Services for Medicare Advantage Subscribers
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 02, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P49R1-20 CERiS Review of High Dollar Claims
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 02, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P78-20 Reminder: New Prior Authorization Timeframes Required by Legislation
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 02, 2020